lapatinib has been researched along with Colorectal Cancer in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (6.90) | 29.6817 |
| 2010's | 19 (65.52) | 24.3611 |
| 2020's | 8 (27.59) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, R; Cai, H; Gu, Y; Hu, F; Li, C; Lin, Q | 1 |
| André, T; Cervera, P; Cohen, R; Spitzer, E | 1 |
| Bakalli, G; Buchs, N; Docquier, M; Guerrier, S; Hany, D; Huelsken, J; Koessler, T; McKee, T; Norkin, M; Nowak-Sliwinska, P; Ramzy, GM; Ris, F; Rubbia-Brandt, L; Tihy, M; Toso, C; Voirol, L | 1 |
| Beißbarth, T; Bohnenberger, H; Conradi, LC; Gaedcke, J; Ghadimi, MB; Grade, M; Kisly, M; König, A; Liersch, T; Metzger, AL; Middel, P; Rüschoff, J; Spitzner, M | 1 |
| De Cuyper, A; Machiels, JP; Van Den Eynde, M | 1 |
| Beijnen, JH; Bernards, R; Huijberts, SCFA; Huitema, ADR; Marchetti, S; Monkhorst, K; Opdam, FL; Pulleman, S; Rosing, H; Schellens, JHM; Steeghs, N; Thijssen, B; van Brummelen, EMJ; van Geel, RMJM | 1 |
| Aglietta, M; Ciardiello, F; Lonardi, S; Marsoni, S; Martino, C; Sartore-Bianchi, A; Siena, S | 1 |
| Amatu, A; Bardelli, A; Bencardino, K; Bergamo, F; Bonazzina, E; Bonoldi, E; Cappello, G; Cassingena, A; Ciardiello, F; Fenocchio, E; Ghezzi, S; Leone, F; Lonardi, S; Marrapese, G; Marsoni, S; Martinelli, E; Martino, C; Mauri, G; Regge, D; Sartore-Bianchi, A; Siena, S; Siravegna, G; Torri, V; Tosi, F; Troiani, T; Trusolino, L; Valtorta, E; Vanzulli, A; Zagonel, V | 1 |
| Fakih, M; Wang, C | 1 |
| Fakih, MG | 1 |
| Chu, E | 1 |
| Amatu, A; Arcella, P; Balsamo, A; Bardelli, A; Bartolini, A; Bertotti, A; Bonazzina, E; Cappello, G; Cassingena, A; Corti, G; Crisafulli, G; Di Nicolantonio, F; Fairclough, S; Ghezzi, S; Lanman, RB; Lazzari, L; Leone, F; Lodi, F; Lonardi, S; Lorenzato, A; Marsoni, S; Martino, C; Montone, M; Mussolin, B; Nagy, RJ; Regge, D; Rospo, G; Russo, M; Sartore-Bianchi, A; Siena, S; Siravegna, G; Truini, M; Trusolino, L; Valtorta, E; Vanzati, A; Vanzulli, A; Zagonel, V | 1 |
| Barault, L; Bardelli, A; Bartolini, A; Buscarino, M; Corti, G; Crisafulli, G; Di Nicolantonio, F; Isella, C; Marsoni, S; Medico, E; Montone, M; Mussolin, B; Negrino, C; Novara, L; Rospo, G; Siena, S; Siravegna, G | 1 |
| Arcella, P; Arena, S; Barbosa, F; Bardelli, A; Bertotti, A; Cancelliere, C; Cassingena, A; Corti, G; Di Nicolantonio, F; Durinikova, E; Garnett, MJ; Isella, C; Lazzari, L; Linnebacher, M; Medico, E; Montone, M; Novara, L; Picco, G; Sartore-Bianchi, A; Siena, S; Trusolino, L; Zanella, ER | 1 |
| Piccart, M | 1 |
| Deeken, JF; He, AR; Hwang, J; Marshall, JL; Pishvaian, MJ; Ramos, C; Steadman, K; Subramaniam, D; Urso, CE; Wang, H; Wang, Y | 1 |
| Chen, YC; Chin, SY; Chou, CL; Jiang, MC; Lee, WR; Liu, KH; Shen, SC; Shih, YH; Tseng, JT | 1 |
| Aprile, G; Bencardino, K; Ciardiello, F; Frau, B; Gambacorta, M; Garufi, C; Graiff, C; Grigioni, W; Labianca, R; Lauricella, C; Leone, F; Lonardi, S; Loupakis, F; Marsoni, S; Martino, C; Mosconi, S; Noe, J; Penaullt-Llorca, F; Pinto, C; Racca, P; Risio, M; Rugge, M; Sartore-Bianchi, A; Siena, S; Tonini, G; Truini, M; Valtorta, E; Veronese, S; Viale, G; Zagonel, V | 1 |
| Amatu, A; Bardelli, A; Bencardino, K; Bergamo, F; Bertotti, A; Cassingena, A; Ciardiello, F; Comoglio, PM; Depetris, I; Ghezzi, S; Lauricella, C; Leone, F; Lonardi, S; Marrapese, G; Marsoni, S; Martinelli, E; Martino, C; Palmeri, L; Racca, P; Regge, D; Sartore-Bianchi, A; Siena, S; Siravegna, G; Torri, V; Troiani, T; Trusolino, L; Valtorta, E; Vanzulli, A; Veronese, S; Zagonel, V | 1 |
| Chen, Y; Chen, ZS; Huang, JR; Jiang, QW; Li, Y; Qin, WM; Qiu, JG; Shi, Z; Wang, K; Wang, YJ; Wei, MN; Yang, DH; Yang, Y; Zhang, WJ; Zheng, DW | 1 |
| El-Khoueiry, A; Fazzone, W; LaBonte, MJ; Ladner, RD; Lenz, HJ; Louie, SG; Russell, J; Wilson, PM | 1 |
| Alberti, D; Bowen, CJ; Dar, MM; Dennie, TW; Fleming, RA; Holen, KD; Loconte, N; Mulkerin, D; Oliver, K | 1 |
| Dennie, T; Holen, KD; Mohammed, TA | 1 |
| Bigot, L; Boige, V; Bonhomme-Faivre, L; Chu, C; Farinotti, R; Goéré, D; Gonin, P; Marion, S; Noël-Hudson, MS; Polrot, M | 1 |
| Belliere, A; Chevrier, R; Chollet, P; Dillies, AF; Durando, X; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Thivat, E; Van Praagh, I | 1 |
| Ashraf, SQ; Bodmer, WF; Mortensen, NJ; Nicholls, AM; Ntouroupi, TG; Wilding, JL | 1 |
| Berlin, JD; Lockhart, AC; Lockhart, C | 1 |
| Brose, MS; Flaherty, KT | 1 |
4 review(s) available for lapatinib and Colorectal Cancer
| Article | Year |
|---|---|
[Targeting HER2 in colorectal cancer].
Topics: Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms; Female; Humans; Lapatinib; Prognosis; Receptor, ErbB-2; Trastuzumab | 2023 |
HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Gene Amplification; Humans; Lapatinib; Panitumumab; Predictive Value of Tests; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Receptor, ErbB-2; Retrospective Studies; Trastuzumab | 2020 |
The epidermal growth factor receptor as a target for colorectal cancer therapy.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Transformation, Neoplastic; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Organic Chemicals; Panitumumab; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction | 2005 |
Her-2 targeted therapy: beyond breast cancer and trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Female; Humans; Lapatinib; Morpholines; Neoplasms; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2006 |
10 trial(s) available for lapatinib and Colorectal Cancer
| Article | Year |
|---|---|
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Lapatinib; Male; Middle Aged; Mutation; Pancreatic Neoplasms; Pharmacogenetics; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Treatment Outcome | 2020 |
Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Central Nervous System Neoplasms; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Male; Middle Aged; Protein Kinase Inhibitors; Receptor, ErbB-2; Recurrence; Trastuzumab; Treatment Outcome | 2020 |
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain; Brain Neoplasms; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Immunohistochemistry; Lapatinib; Magnetic Resonance Imaging; Male; Middle Aged; Progression-Free Survival; Proto-Oncogene Proteins p21(ras); Receptor, ErbB-2; Trastuzumab | 2020 |
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Class I Phosphatidylinositol 3-Kinases; Clinical Decision-Making; Colorectal Neoplasms; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gene Amplification; Humans; Italy; Lapatinib; Liquid Biopsy; Liver Neoplasms; Magnetic Resonance Imaging; Male; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Predictive Value of Tests; Progression-Free Survival; Protein Kinase Inhibitors; ras Proteins; Receptor, ErbB-2; Risk Factors; Signal Transduction; Time Factors; Tomography, X-Ray Computed; Trastuzumab; Treatment Outcome; Tumor Cells, Cultured | 2018 |
A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Circulating Tumor DNA; Colorectal Neoplasms; DNA Copy Number Variations; Gene Dosage; Genomics; Genotyping Techniques; High-Throughput Nucleotide Sequencing; Humans; Italy; Lapatinib; Mutation; Neoplasm Recurrence, Local; Patient Selection; Precision Medicine; Prognosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Workflow | 2019 |
A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biopsy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Female; Genetic Variation; Genotype; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pharmacogenetics; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2015 |
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Colorectal Neoplasms; Female; Gene Expression Profiling; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lapatinib; Male; Middle Aged; Patient Selection; Quinazolines; Receptor, ErbB-2; ROC Curve; Trastuzumab | 2015 |
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Codon; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lapatinib; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Trastuzumab | 2016 |
A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Drug Monitoring; Female; Fluorouracil; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Quinazolines | 2011 |
Activity of oxaliplatin plus capecitabine (CapeOx) with lapatinib for metastatic colorectal cancer: results from two patients treated on a clinical study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Liver Neoplasms; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2011 |
15 other study(ies) available for lapatinib and Colorectal Cancer
| Article | Year |
|---|---|
Based on lapatinib innovative near-infrared fluorescent probes targeting HER1/HER2 for in vivo tumors imaging.
Topics: Animals; Biosensing Techniques; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colorectal Neoplasms; Fluorescent Dyes; Humans; Lapatinib; Lung Neoplasms; Mice; Mice, Nude | 2022 |
Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma.
Topics: Colorectal Neoplasms; Humans; Lapatinib; Liver Neoplasms; Organoids; Precision Medicine | 2023 |
Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Caco-2 Cells; Cell Survival; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; HCT116 Cells; HT29 Cells; Humans; Lapatinib; Molecular Targeted Therapy; Oxaliplatin; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Trastuzumab | 2019 |
Response to Trastuzumab and Lapatinib in a Metastatic Colorectal Cancer Harboring HER2 Amplification and HER2 S310F Mutation.
Topics: Colorectal Neoplasms; Humans; Lapatinib; Mutation; Receptor, ErbB-2; Trastuzumab | 2021 |
Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer.
Topics: Antibodies, Monoclonal, Humanized; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Male; Middle Aged; Protein Kinase Inhibitors; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2018 |
How I treat chemorefractory metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lymphatic Metastasis; Neoplasm Staging; Nivolumab; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Pyridines; Pyrrolidines; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Thymine; Trastuzumab; Trifluridine; Uracil; Vascular Endothelial Growth Factor Receptor-1 | 2018 |
Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cohort Studies; Colon; Colorectal Neoplasms; Drug Resistance, Neoplasm; Exome Sequencing; Female; Gene Dosage; Humans; Lapatinib; Male; Mice; Microsatellite Instability; Middle Aged; Precision Medicine; Primary Cell Culture; Rectum; RNA-Seq; Trastuzumab; Treatment Outcome; Werner Syndrome Helicase; Xenograft Model Antitumor Assays | 2019 |
Personalised cancer management: closer, but not here yet.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Molecular Targeted Therapy; Precision Medicine; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.
Topics: Animals; Antibodies, Neoplasm; Cell Line, Tumor; Cell Proliferation; Cellular Apoptosis Susceptibility Protein; Colorectal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Lapatinib; Male; Melanoma; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Quinazolines; Sorafenib; Sulfonamides; Sunitinib; Vemurafenib; Xenograft Model Antitumor Assays | 2015 |
Colorectal Cancer Yields to Dual HER2 Blockade.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Humans; Lapatinib; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2016 |
Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Female; HCT116 Cells; HT29 Cells; Humans; Inhibitory Concentration 50; Lapatinib; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neovascularization, Pathologic; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; ErbB Receptors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lapatinib; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mutation; Neoplasm Transplantation; Panobinostat; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2011 |
Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Colorectal Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Lapatinib; Mice; Mice, Nude; Mutation; Quinazolines; ras Proteins; Sirolimus; Xenograft Model Antitumor Assays | 2013 |
Adherence with oral oncologic treatment in cancer patients: interest of an adherence score of all dosing errors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Male; Medication Adherence; Medication Errors; Middle Aged; Patient Compliance; Pilot Projects; Prognosis; Prospective Studies; Quinazolines | 2013 |
Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Immune System; Lapatinib; Models, Genetic; Oligonucleotide Array Sequence Analysis; Polymorphism, Genetic; Quinazolines; Trastuzumab | 2012 |